Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2499 • 2019 ACR/ARP Annual Meeting
Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis
Winifred Badaiki¹, Quan Li ², Tanya Burry ¹, Fiona Landells ¹, Rachel Gehue ¹, Cindy Penney ³, DIanne Codner ¹, Amanda Dohey ¹, Kerri Smith ¹, Fatima Abji ⁴, Dafna Gladman ⁵, Darren O'Rielly ¹, Vinod Chandran ⁶ and Proton Rahman ⁷, ¹Memorial University, St. Johns, Canada, ²Toronto Western Hospital, Toronto, Canada, ³Memorial University, St Johns, Canada, ⁴Memorial University, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, Canada, ⁷Memorial University, St. Johns, NL, Canada
Background/Purpose: Delay in diagnosis of psoriatic arthritis (PsA) has been shown to contribute to poor radiographic and functional outcome and less successful response to treatment…
Abstract Number: 2853 • 2019 ACR/ARP Annual Meeting
The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound
Samantha Sarabia ¹, Chandra Farrer ², Jensen Yeung ³, Richard Cook ⁴, Ker-Ai Lee ⁵, Dana Jerome ³ and Lihi Eder⁶, ¹Faculty of Medicine, Queens University, Kingston, Canada, ²University of Toronto, Toronto, Canada, ³University of Toronto, Toronto, ⁴University of Waterloo, Waterloo, Canada, ⁵University of Waterloo, Waterloo, ⁶Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada
Background/Purpose: There is limited information about the constellation of musculoskeletal symptoms experienced by patients with early psoriatic arthritis (PsA). This study aims to describe the…
Abstract Number: 628 • 2019 ACR/ARP Annual Meeting
Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Alexis Ogdie¹, Sofia Pedro ² and Kaleb Michaud ³, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases and University of Nebraska Medical Center, Wichita, KS
Background/Purpose: Pain is the most common symptom among patients with inflammatory arthritis (IA) and residual pain is common in patients IA despite appropriate treatment. Opiate…
Abstract Number: 1088 • 2019 ACR/ARP Annual Meeting
Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg ¹, Lennart Jacobsson ², Michael J. Nissen ³, Eirik Kristianslund ⁴, Herman Mann ⁵, Maria José Santos ⁶, Manuel Pombo-Suarez ⁷, Dan Nordström ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Fatos Onen ¹¹, Catalin Codreanu ¹², Anne Gitte Loft ¹³, Ulf Lindström ¹⁴, Burkhard Moeller ¹⁵, Joe Sexton ¹⁶, Karel Pavelka ⁵, Anabela Barcelos ¹⁷, Carlos Sánchez-Piedra ¹⁸, Kari K. Eklund ¹⁹, Matija Tomsic ²⁰, Thorvardur J Love ²¹, Gercek Can ²², Ruxandra IONESCU ²³, Marleen van de Sande ²⁴, Irene van der Horst-Bruinsma ²⁵, Gareth Jones ²⁶, Florenzo Iannone ²⁷, Brigitte Michelsen ¹, Lise Hyldstrup ²⁸, Niels Steen Krogh ²⁹, Mikkel Østergaard ³⁰ and Merete Lund Hetland ³¹, ¹EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ²Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ³University Hospital Geneva, Geneva, Switzerland, ⁴Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ⁵Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Rheumatology Unit, Clinical University Hospital of Santiago de Compostela,, Santiago, Spain, ⁸Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁴University of Gothenburg, Gothenburg, Sweden, ¹⁵University Hospital Bern, Bern, Switzerland, ¹⁶Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ¹⁷Centro Hospitalar Baixo Vouga | iBemed, University of Aveiro, Aveiro, Portugal, ¹⁸Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ¹⁹ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ²⁰Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²²TURKBIO Registry and Division of Rheumatology, School of Medicine Dokuz Eylul University,, Izmir, Turkey, ²³SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁴Amsterdam UMC, Amsterdam, Netherlands, ²⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ²⁶University of Aberdeen, Aberdeen, United Kingdom, ²⁷Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ²⁹Zitelab / DANBIO, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³¹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Tumour necrosis factor inhibitors (TNFi) are efficacious in patients with psoriatic arthritis (PsA), but some patients switch to a different TNFi because of adverse…
Abstract Number: 1489 • 2019 ACR/ARP Annual Meeting
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study
Tim Jansen¹, Eric-Jan Kroot ², Arie van Vliet ³, Jan Pander ⁴ and Marijn Vis ⁵, ¹Viecuri MC, Venlo, Netherlands, ²Elkerliek, Helmond, Netherlands, ³Celgene, Utretcht, Netherlands, ⁴Celgene, Utrecht, Netherlands, ⁵ErasmusMC, Rotterdam, Netherlands
Background/Purpose: Recent data suggest that patients with moderately active psoriatic arthritis (PsA) and a limited number of active joints have a high likelihood of achieving…
Abstract Number: 1538 • 2019 ACR/ARP Annual Meeting
The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Andrew Price¹, Vanya Wagler ², Chase Donaldson ¹ and Patrick Mastin ¹, ¹William Beaumont Army Medical Center, El Paso, TX, ²United Regional Physician Group, Wichita Falls, TX
Background/Purpose: Apremilast is a novel oral phosphodiesterase 4 inhibitor that is used for plaque psoriasis (PsO) and psoriatic arthritis (PsA). This medicine is unique in…
Abstract Number: 2440 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
Timothy Kwok¹, Justine (Yang) Ye ², Daniel Pereira ² and Dafna Gladman ³, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Evidence thus far on the effect of psoriatic arthritis (PsA) on bone mineral density (BMD) has been inconsistent. There is also insufficient guidance surrounding…
Abstract Number: 2457 • 2019 ACR/ARP Annual Meeting
Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study
Danielle Korkus ¹, Tal Gazitt ², Arnon Dov Cohen ³, Ilan Feldhamer ⁴, Idit Lavi ², Amir Haddad ², Sari Greenberg-Dotan ⁴, Erez Batat ⁴ and Devy Zisman⁵, ¹The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, ²Carmel Hospital, Haifa, Israel, ³Central Headquarters, Clalit Health Services,Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel, Tel Aviv, Israel, ⁴Central Headquarters, Clalit Health Services, Tel Aviv, Israel, ⁵Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel
Background/Purpose: Patients with psoriasis and psoriatic arthritis (PsA) can develop a variety of comorbidities which may influence the therapeutic regimen and affect treatment results. Previous…
Abstract Number: 2479 • 2019 ACR/ARP Annual Meeting
Unmet Treatment Needs in Patients with Psoriatic Arthritis
Daniel Aletaha¹, Mihalina Georgallis ², Matthew Wallace ², Patrick Zueger ³ and Ruth Zeidman ², ¹Medical University of Vienna, Vienna, Austria, ²Covance Market Access & Phase IV Solutions, London, United Kingdom, ³AbbVie Inc., North Chicago
Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current…
Abstract Number: 2500 • 2019 ACR/ARP Annual Meeting
Current Smoking Status Increases the Risk of Axial Psoriatic Arthritis: An Explanation to Smoking Paradox
Dilek Solmaz ¹, Umut Kalyoncu ², Ilaria Tinazzi ³, Sibel Bakirci ⁴, Ozun Bayindir ⁵, Atalay Dogru ⁶, Ediz Dalkılıç ⁷, Gezmiş Kimyon ⁸, Cem Ozisler ⁹, Gozde Cetin ¹⁰, Levent Kilic ¹¹, Ahmet Omma ¹², Meryem Can ¹³, Sema Yılmaz ¹⁴, Abdulsamet Erden ¹⁵ and Sibel Zehra Aydin¹⁶, ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Hacettepe University Department of Rheumatology, Ankara, Turkey, ³Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Verona, Italy, ⁴Antalya Education and Research Hospital, Antalya, Turkey, ⁵Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁶Suleyman Demirel University, Department of Internal Medicine, Division of Rheumatology, Isparta, Turkey, ⁷Uludağ University, Bursa, Turkey, ⁸Mustafa Kemal University, Hatay, Turkey, ⁹Diskapi Yildirim Beyazit Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, ¹⁰Kahramanmaras Sutcu Imam University, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, ¹¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹²Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹³Marmara University, Division of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ¹⁴Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ¹⁵Hacettepe University, Ankara, Turkey, ¹⁶University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada
Background/Purpose: Smoking has been shown to be associated with an increased risk of psoriatic arthritis (PsA) in the general population, but there are controversies among patients…
Abstract Number: 2854 • 2019 ACR/ARP Annual Meeting
Delay Between the Onset of Psoriasis and Arthritis in PsA Patients from the PsART International Cohort
Koray Tascilar¹, Sibel Zehra Aydin ², Servet Akar ³, Kenan Aksu ⁴, Sibel Bakirci ⁵, Ozun Bayindir ⁶, Meryem Can ⁷, Gozde Cetin ⁸, Muhammet Çınar ⁹, Ediz Dalkılıç ¹⁰, Atalay Dogru ¹¹, Abdulsamet Erden ¹², Emine Duygu Ersözlü ¹³, Şükran Erten ¹⁴, Timuçin Kaşifoğlu ¹⁵, Gezmiş Kimyon ¹⁶, Orhan Küçükşahin ¹⁷, Ahmet Omma ¹⁸, Cem Ozisler ¹⁹, Soner Senel ²⁰, Dilek Solmaz ²¹, Emine Figen Tarhan ²², Ilaria Tinazzi ²³, Sule Yavuz ²⁴, Sema Yılmaz ²⁵ and Umut Kalyoncu ²⁶, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ²University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ³Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ⁴Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, ⁵Antalya Education and Research Hospital, Antalya, Turkey, ⁶Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁷Marmara University, Division of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ⁸Kahramanmaras Sutcu Imam University, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, ⁹University of Medical Sciences, Ankara, Turkey, ¹⁰Uludağ University, Bursa, Turkey, ¹¹Suleyman Demirel University, Department of Internal Medicine, Division of Rheumatology, Isparta, Turkey, ¹²Hacettepe University, Ankara, Turkey, ¹³Adana State Hospital, Adana, Turkey, ¹⁴Yıldırım Beyazıt University, Ankara, Turkey, ¹⁵Eskişehir Osmangazi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Eskişehir, Turkey, ¹⁶Mustafa Kemal University, Hatay, Turkey, ¹⁷Liv Hospital, Ankara, Turkey, ¹⁸Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁹Diskapi Yildirim Beyazit Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, ²⁰Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, ²¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²²Mugla Sitki Kocman University, Department of Internal Medicine, Division of Rheumatology Mugla,, Mugla, Turkey, ²³Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Verona, Italy, ²⁴Uppsala University, Istanbul, Turkey, ²⁵Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, ²⁶Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Psoriatic arthritis is a heterogenous disorder not only with respect to patterns and components of musculoskeletal involvement but also with respect to types of…
Abstract Number: 823 • 2019 ACR/ARP Annual Meeting
The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Lingyi Li¹, Na Lu ¹, Eric Sayre ¹, Hui Xie ², Diane Lacaille ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…
Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Linh Truong¹, Nicole Ridolfi ², Eugenia Chen ² and Maida wong ³, ¹University of California, Irvine, San Diego, CA, ²University of California, Irvine, Orange, ³Tibor Rubin Veterans Affairs Medical Center, Long Beach
Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…
Abstract Number: 1490 • 2019 ACR/ARP Annual Meeting
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Lihi Eder¹, Alexis Ogdie ² and Yujie Zhong ³, ¹Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ²Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³School of Statistics and Management, Shanghai University of Finance and Economics, Cambridge, China (People's Republic)
Background/Purpose: The prevalence of depression is increased in patients with psoriatic arthritis (PsA). Little is known about the impact of effective control of inflammation on…
Abstract Number: 1541 • 2019 ACR/ARP Annual Meeting
Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis
Keith Betts ¹, Pankaj Patel², Jinlin Song ¹, Jing Zhao ³, Yan Wang ¹, Jenny Griffith ² and Eric Wu ⁴, ¹Analysis Group, Inc., Los Angeles, CA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Denver, CO, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Clinical studies have shown that a large proportion of psoriatic arthritis (PsA) patients treated with apremilast failed to achieve improved physical function or experienced…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].